VICC selected to administer FDA-approved CAR T therapy for treatment of lymphoma patientsNews-Medical.netVanderbilt-Ingram Cancer Center (VICC) has been selected as one of the few authorized treatment centers in the United States approved to administer… Continue reading
VICC selected to administer FDA-approved CAR T therapy for treatment of lymphoma patientsNews-Medical.netVanderbilt-Ingram Cancer Center (VICC) has been selected as one of the few authorized treatment centers in the United States approved to administer… Continue reading
Cutting-edge immunotherapy treatment approved for another deadly cancerNew Haven RegisterThe FDA approval is the latest step forward for the fast-moving field of immunotherapy, which aims to bolster the immune system to attack malignancies. CAR T-cell … Continue reading
Cutting-edge immunotherapy treatment approved for another deadly cancerNew Haven RegisterThe FDA approval is the latest step forward for the fast-moving field of immunotherapy, which aims to bolster the immune system to attack malignancies. CAR T-cell … Continue reading
Synthetic Biology Market Projected to Exhibit a Cultivate CAGR During 2013-2019Digital JournalAlbany, NY — (SBWIRE) — 10/25/2017 — The global synthetic biology market is projected to grow remarkably, says a report from Transparency Market Research (… Continue reading
Fortune |
Scientists Are Making Pigs Less Fatty for a Very Important Reason
Fortune There’s been a one-two punch of significant developments in the brave new world of CRISPR gene editing this week—and one of them potentially includes the saddening/encouraging prospect of less fatty bacon and pork products sometime in the future … Scientists Created Low-Fat Pigs by Editing Their Genes With CRISPRTIME CRISPR‘d pigs could produce low-fat baconTechCrunch Bacon that’s healthier but still tasty? It’s possible as scientists create diet pigsSacramento Bee NPR –GenomeWeb –Proceedings of the National Academy of Sciences –NPR all 68 news articles » |
|
Shire Receives Orphan Drug Designation for Gene Therapy Candidate SHP654 (BAX 888) for the Treatment of …
Markets Insider Lexington, MA – October 25, 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotechnology leader in rare diseases, today announced the U.S. Food and Drug Administration (FDA) awarded Orphan Drug Designation to Shire’s gene therapy … |